Shattuck Labs (NASDAQ:STTK) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Shattuck Labs (NASDAQ:STTK) released its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04), FiscalAI reports.

Shattuck Labs Trading Down 12.8%

Shares of STTK stock traded down $0.66 during trading hours on Thursday, reaching $4.49. 1,434,725 shares of the stock were exchanged, compared to its average volume of 971,046. Shattuck Labs has a 12-month low of $1.72 and a 12-month high of $8.33. The company’s 50-day moving average price is $6.13 and its 200-day moving average price is $6.02. The firm has a market capitalization of $450.62 million, a price-to-earnings ratio of -8.80 and a beta of 1.21.

Analysts Set New Price Targets

Several equities analysts have recently commented on STTK shares. JPMorgan Chase & Co. initiated coverage on shares of Shattuck Labs in a report on Friday, July 24th. They issued an “overweight” rating and a $10.00 target price on the stock. Leerink Partners began coverage on shares of Shattuck Labs in a research note on Monday, July 20th. They set an “outperform” rating and a $16.00 target price for the company. Wedbush raised their target price on shares of Shattuck Labs from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, October 2nd. Wall Street Zen downgraded shares of Shattuck Labs from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Needham & Company LLC boosted their price target on shares of Shattuck Labs from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $13.70.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.